EU Project Explores How To Engage Patient Organizations In Drug Development, Approval
This article was originally published in SRA
Executive Summary
As groups and bodies with an interest in drug development increasingly recognize the benefits of incorporating the views of patients in their decision-making processes, work is under way in the EU to develop guidelines on how patient organizations should interact with the pharmaceutical industry, ethics committees, health technology assessment bodies and regulators.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.